A pivotal phase 3 study of thymosin beta 4 (RGN 259) for Dry eyes : ARISE-3.
Phase of Trial: Phase III
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Timbetasin (Primary)
- Indications Dry eyes
- Focus Registrational; Therapeutic Use
- Acronyms ARISE-3
- Sponsors ReGenTree
- 12 Feb 2019 Status changed from planning to recruiting, according to a RegeneRx Biopharmaceuticals media release.
- 12 Feb 2019 According to a RegeneRx Biopharmaceuticals media release, treatment of the subjects in the trial will be completed in the first half of 2020.
- 04 Jan 2019 According to a RegeneRx Biopharmaceuticals media release, Gtree is not designing ARISE-3 to do more than the FDA requires for products currently on the market.